Company History and Business Overview
Adverum Biotechnologies, Inc. (ADVM) is a clinical-stage biopharmaceutical company that is pioneering the use of gene therapy to address highly prevalent ocular diseases. With a focus on preserving sight for life, Adverum is leveraging its proprietary adeno-associated virus (AAV) vector platform to develop transformative treatment options for patients suffering from conditions like wet age-related macular degeneration (wet AMD).
Adverum Biotechnologies, Inc. was incorporated in Delaware on July 17, 2006 and is headquartered in Redwood City, California. The company was founded with the goal of establishing gene therapy as a new standard of care for highly prevalent ocular diseases. Adverum has focused its research and development efforts on developing gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein.
In November 2018, Adverum initiated the OPTIC trial, an open-label, dose-ranging trial evaluating the safety and efficacy of its lead product candidate, ixoberogene soroparvovec (Ixo-vec), in subjects with wet age-related macular degeneration (wet AMD) who have demonstrated responsiveness to anti-VEGF treatment. The OPTIC trial was a two-year trial, which the last subject completed in June 2022, and the company continues to follow subjects in an extension trial.
In September 2022, Adverum dosed the first subject in its LUNA Phase 2 trial of Ixo-vec. The LUNA trial is a multicenter, double-masked, randomized, parallel-group trial evaluating two doses of Ixo-vec. In August 2023, Adverum announced that LUNA was fully enrolled, with a total of 60 subjects randomized equally between the two doses.
Adverum has faced several challenges in its development of Ixo-vec and other product candidates. In 2021, the company announced that it was discontinuing development of Ixo-vec for the treatment of diabetic macular edema after a dose-limiting toxicity was observed in its INFINITY trial. Additionally, the company has encountered difficulties enrolling patients in its clinical trials, which has caused delays in its development timeline.
Despite these challenges, Adverum has achieved some important regulatory designations for Ixo-vec, including Fast Track designation from the FDA in 2018, Priority Medicines (PRIME) designation from the EMA in 2022, and an Innovation Passport under the UK’s Innovative Licensing and Access Pathway in 2023. These designations are intended to enhance support for the research and development of Ixo-vec and potentially expedite the regulatory review process.
Wet AMD is a leading cause of blindness in patients over 65 years of age, with a global prevalence of approximately 20 million individuals. The current standard of care for wet AMD involves regular, repeated intravitreal (IVT) injections of anti-VEGF therapies like Regeneron’s EYLEA (aflibercept) and Roche’s Lucentis (ranibizumab). While effective, this treatment regimen places a significant burden on patients due to the frequency of invasive IVT injections.
Ixo-vec aims to address this burden by providing long-lasting anti-VEGF expression from a single IVT administration. The therapy utilizes an engineered, proprietary AAV vector (AAV.7m8) to transduce retinal cells and induce sustained production of the aflibercept protein. This approach has the potential to maintain visual and anatomic outcomes while significantly reducing the treatment burden for patients with wet AMD.
Adverum has made meaningful progress in the clinical development of Ixo-vec. The therapy is currently being evaluated in the LUNA Phase 2 clinical trial, which is assessing two different dose levels (2E11 and 6E10) in combination with prophylactic corticosteroid regimens. In July 2024, the company announced positive 26-week interim data from LUNA, which showed that both Ixo-vec dose levels maintained visual and anatomic endpoints and demonstrated potential best-in-class injection-free rates and reduction in injection burden.
Furthermore, Adverum continues to report encouraging long-term data from the OPTIC Phase 1 trial of Ixo-vec. The most recent 4-year follow-up data, announced in November 2024, showed sustained therapeutic efficacy and a favorable safety profile, with the majority of patients remaining free of inflammation through the extended follow-up period.
Based on these positive clinical results, Adverum plans to initiate its pivotal ARTEMIS Phase 3 program for Ixo-vec in the first half of 2025. The company has also received several regulatory designations for Ixo-vec, including Fast Track from the FDA, Priority Medicines (PRIME) from the European Medicines Agency, and Regenerative Medicine Advanced Therapy (RMAT) from the FDA, which are intended to expedite the development and review of the therapy.
Financial Performance and Liquidity
Adverum’s financial performance has been characterized by consistent net losses as the company has dedicated significant resources to the development of its gene therapy pipeline. For the nine months ended September 30, 2024, the company reported a net loss of $70.4 million, compared to a net loss of $93.4 million for the same period in the prior year.
However, Adverum’s cash position remains robust, with $153.2 million in cash, cash equivalents, and short-term investments as of September 30, 2024. The company believes these funds will be sufficient to fund its planned operations into late 2025, providing a strong financial foundation to support the advancement of Ixo-vec and the company’s other gene therapy programs.
Adverum’s current ratio, a measure of the company’s ability to meet its short-term obligations, stands at 5.82 as of September 30, 2024, indicating a healthy liquidity position. The company’s debt-to-equity ratio is low at 0.07, further demonstrating its financial stability and limited leverage.
For the most recent fiscal year (2023), Adverum reported revenue of $3.60 million, a net loss of $117.17 million, operating cash flow of -$90.90 million, and free cash flow of -$91.71 million. In the most recent quarter (Q3 2024), the company’s revenue was $1.00 million, with a net loss of $27.13 million, operating cash flow of -$21.12 million, and free cash flow of -$21.35 million. These figures represent a year-over-year decrease in revenue, net income, operating cash flow, and free cash flow, primarily due to continued investment in research and development for Ixo-vec.
As of September 30, 2024, Adverum’s cash and cash equivalents stood at $92.85 million. The company’s current ratio and quick ratio were both 5.82, indicating strong short-term liquidity. Adverum does not have any disclosed available credit lines.
It’s worth noting that Adverum generated $1.00 million in license revenue during the three and nine months ended September 30, 2024, related to a milestone payment from its license agreement with Ray Therapeutics, Inc. The company has not yet generated any revenue from product sales, as it does not have any approved products on the market.
Key Risks and Challenges
As with any biotechnology company, Adverum faces several risks and challenges that investors should be aware of. The development of gene therapies, including Ixo-vec, is inherently complex and carries the risk of unexpected safety or efficacy issues that could delay or derail clinical trials and regulatory approvals.
Additionally, Adverum’s reliance on third-party manufacturers and contract research organizations (CROs) introduces supply chain and execution risks that the company must manage effectively. The company’s ability to successfully scale its manufacturing processes and maintain regulatory compliance will be critical to the successful commercialization of its product candidates.
Another key risk is the competitive landscape for the treatment of wet AMD. While Ixo-vec has demonstrated promising results, it will face competition from established therapies like EYLEA and Lucentis, as well as other emerging gene therapy and long-acting delivery approaches. Adverum’s ability to differentiate Ixo-vec and secure favorable reimbursement will be crucial to its commercial success.
Outlook and Anticipated Milestones
Despite the risks, Adverum remains well-positioned to advance its gene therapy pipeline and address the significant unmet need in ocular diseases. The company is on track to initiate its pivotal ARTEMIS Phase 3 trial for Ixo-vec in the first half of 2025, which will evaluate the therapy’s safety and efficacy in a broad patient population.
Additionally, Adverum plans to report 52-week data from the LUNA Phase 2 trial and 4-year data from the OPTIC trial in the fourth quarter of 2024. These updates will provide further insights into the long-term potential of Ixo-vec and the company’s progress toward regulatory submission and approval.
Adverum has also recently bolstered its leadership team with the appointment of Jason L. Mitchell as Chief Commercial Officer, underscoring the company’s commitment to preparing for the potential commercialization of Ixo-vec.
The company’s pipeline beyond Ixo-vec for wet AMD includes early-stage gene therapy programs targeting the treatment of other highly prevalent ocular diseases. Adverum’s core capabilities encompass vector evaluation, cassette engineering, ocular IND-enabling nonclinical and clinical development, scalable process development, assay development, and current Good Manufacturing Practices (GMP) quality control.
Conclusion
Adverum Biotechnologies is at the forefront of gene therapy innovation, leveraging its proprietary AAV platform to develop transformative treatment options for patients with highly prevalent ocular diseases. The company’s lead product candidate, Ixo-vec, has demonstrated promising clinical results in the treatment of wet AMD, a leading cause of blindness in the elderly population.
With a robust financial position, a clear development plan, and a strengthened leadership team, Adverum is well-positioned to continue advancing Ixo-vec and its broader pipeline. As the company prepares to initiate its pivotal Phase 3 program, investors will closely watch for upcoming milestones that could further validate Ixo-vec’s potential to become a best-in-class therapy and establish Adverum as a leader in the gene therapy space.
The positive 26-week interim analysis data from the LUNA Phase 2 trial, announced in July 2024, has provided additional confidence in Ixo-vec’s potential. Both the 2E11 and 6E10 doses demonstrated maintenance of visual and anatomic outcomes, with favorable reductions in annualized anti-VEGF injections and a high percentage of subjects remaining free of injections. Based on these results, Adverum has selected the 6E10 dose for the upcoming Phase 3 pivotal trials.
Furthermore, the FDA’s granting of Regenerative Medicine Advanced Therapy (RMAT) designation for Ixo-vec in August 2024 provides potential benefits such as increased collaboration with the FDA to accelerate development and the possibility of Priority Review. This regulatory support, combined with the company’s strong cash position and focused development strategy, positions Adverum well to potentially bring a transformative therapy to patients with wet AMD and other ocular diseases in the coming years.
Disclaimer: This article is for informational purposes only. It does not constitute financial, legal, or other types of advice. While every effort has been made to ensure the accuracy of the information presented here, the author and the publisher do not make any guarantees about the completeness, reliability, and accuracy of this information.